News

SAA Joins with PatientPoint to Improve Disease Understanding, Treatment at Rheumatology Centers

The Spondylitis Association of America (SAA) and PatientPoint are working to improve spondylitis education, treatment, and support information at rheumatology practices nationwide. The partnership will utilize PatientPoint’s platform, designed to educate and empower patients, caregivers and staff to improve health outcomes and patient experiences in a range of specialties. It will…

Cosentyx Effectively Lowers Disease Activity in nr-axSpA Patients Treated for 1 Year, Phase 3 Trial Reports

Treatment with Novartis’ Cosentyx (secukinumab) significantly reduced disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to new data from the Phase 3 PREVENT trial. The trial achieved its primary endpoint (goal) of Assessment of Spondyloarthritis International Society response criteria (ASAS40) — defined as…

NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC

Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…